Cloud-clone
SKU:PAL154Ra01
Polyclonal Antibody to Fibroblast Growth Factor 15 (FGF15)
Polyclonal Antibody to Fibroblast Growth Factor 15 (FGF15)
Couldn't load pickup availability
Western blotting: 0.5-3µg/mL;
;Immunohistochemistry: 5-30µg/mL;
;Immunocytochemistry: 5-30µg/mL;
;Optimal working dilutions must be determined by end user.
Product No.
PAL154Ra01
Organism Species
Rattus norvegicus (Rat).
Source
Polyclonal antibody preparation
Host
Rabbit
Potency
n/a
Ig Type
IgG
Purification
Antigen-specific affinity chromatography followed by Protein A affinity chromatography
Label
None
Immunogen
RPL154Ra01-Recombinant Fibroblast Growth Factor 15 (FGF15)
Buffer Formulation
0.01M PBS, pH7.4, containing 0.05% Proclin-300, 50% glycerol.
Traits
Liquid
Concentration
0.5mg/ml
Organism Species More
Mus musculus (Mouse), Sus scrofa; Porcine (Pig)
Applications
WB; IHC; ICC; IP.
If the antibody is used in flow cytometry, please check FCM antibodies.
UOM
20µl 100µl 200µl 1ml 10ml
SPECIFITY
The antibody is a rabbit polyclonal antibody raised against FGF15. It has been selected for its ability to recognize FGF15 in immunohistochemical staining and western blotting.
USAGE
Western blotting: 0.01-3µg/mL;
Immunohistochemistry: 5-30µg/mL;
Immunocytochemistry: 5-30µg/mL;
Optimal working dilutions must be determined by end user.
STORAGE
Store at 4°C for frequent use. Stored at -20°C in a manual defrost freezer for two year without detectable loss of activity. Avoid repeated freeze-thaw cycles.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
| Magazine | Citations |
| Endocrinology. | Naringenin Prevents Obesity, Hepatic Steatosis, and Glucose Intolerance in Male Mice Independent of Fibroblast Growth Factor 21 PubMed: 25774553 |
| Inflammatory Bowel Diseases | Alterations in Enterohepatic Fgf15 Signaling and Changes in Bile Acid Composition Depend on Localization of Murine Intestinal Inflammation pubmed:27580383 |
| J Lipid Res. | Commensal bacteria at the crossroad between cholesterol homeostasis and chronic inflammation in atherosclerosis. pubmed:28130274 |
| BMC Endocrine Disorders | The relationship between bile acid concentration, glucagon-like-peptide 1, fibroblast growth factor 15 and bile acid receptors in rats during progression of glucose intolerance 10.1186/s12902-017-0211-5 |
| Journal of Physiology and Biochemistry | The ileal FGF15/19 to hepatic FGFR4 axis regulates liver regeneration after partial hepatectomy in mice Pubmed:29468415 |
| Developmental Cell | FGF15 Activates Hippo Signaling to Suppress Bile Acid Metabolism and Liver Tumorigenesis Pubmed: 30745141 |
| Endocrinology | Interactions between the gravitostat and the fibroblast growth factor system for the regulation of body weight |
| Food & Function | Lactoferrin promotes bile acid metabolism and reduces hepatic cholesterol deposition by inhibiting the farnesoid X receptor (FXR)-mediated enterohepatic axis Pubmed: 31626262 |
| Journal of Translational Medicine | Gut microbiota from coronary artery disease patients contributes to vascular dysfunction in mice by regulating bile acid metabolism and immune activation Pubmed: 33036625 |
| Chin Med | Si-Wu-Tang ameliorates fibrotic liver injury via modulating intestinal microbiota and bile acid homeostasis 34736501 |
| Int J Biol Sci | Dynamics of the gut-liver axis in rats with varying fibrosis severity Pubmed:35637968 |
Share
